Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333–59. https://doi.org/10.1001/archneur.1964.00460160003001.

Article  CAS  PubMed  Google Scholar 

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1–9. https://doi.org/10.1212/wnl.47.1.1.

Article  CAS  PubMed  Google Scholar 

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I, Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–64. https://doi.org/10.1002/mds.26987.

Article  PubMed  PubMed Central  Google Scholar 

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU, Movement Disorder Society-endorsed PSP Study Group. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord. 2019;34(8):1228–32. https://doi.org/10.1002/mds.27666.

Article  PubMed  PubMed Central  Google Scholar 

Ali F, Martin PR, Botha H, Ahlskog JE, Bower JH, Masumoto JY, Maraganore D, Hassan A, Eggers S, Boeve BF, Knopman DS, Drubach D, Petersen RC, Dunkley ED, van Gerpen J, Uitti R, Whitwell JL, Dickson DW, Josephs KA. Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord. 2019;34(8):1144–53. https://doi.org/10.1002/mds.27619. Epub 2019 Feb 6. PMID: 30726566; PMCID: PMC6688972.

Article  PubMed  PubMed Central  Google Scholar 

Lyons S, Trépel D, Lynch T, Walsh R, O’Dowd S. The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis. J Neurol. 2023;270(9):4451–65. https://doi.org/10.1007/s00415-023-11791-2.

Article  PubMed  PubMed Central  Google Scholar 

Driver-Dunckley ED, Zhang N, Serrano GE, Dunckley NA, Sue LI, Shill HA, Mehta SH, Belden C, Tremblay C, Atri A, Adler CH, Beach TG. Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. J Neuropathol Exp Neurol. 2023;82(5):438–51. https://doi.org/10.1093/jnen/nlad025.

Article  PubMed  Google Scholar 

• Chen QS, Li XY, Li L, Lu JY, Sun YM, Liu FT, Zuo CT, Wang J. Dopamine transporter imaging in progressive supranuclear palsy: severe but nonspecific to subtypes. Acta Neurol Scand. 2022;146(3):237–45. https://doi.org/10.1111/ane.13653. Highlights how DAT scan changes (specifically more severe dopaminergic transporter loss in the striatum) can be seen when comparing PSP to PD and MSA-P.

Article  CAS  PubMed  Google Scholar 

Massey LA, Jäger HR, Paviour DC, O’Sullivan SS, Ling H, Williams DR, Kallis C, Holton J, Revesz T, Burn DJ, Yousry T, Lees AJ, Fox NC, Micallef C. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology. 2013;80(20):1856–61. https://doi.org/10.1212/WNL.0b013e318292a2d2.

Article  PubMed  PubMed Central  Google Scholar 

Kaasinen V, Kangassalo N, Gardberg M, Isotalo J, Karhu J, Parkkola R, Sonninen P. Midbrain-to-pons ratio in autopsy-confirmed progressive supranuclear palsy: replication in an independent cohort. Neurol Sci. 2015;36(7):1251–3. https://doi.org/10.1007/s10072-015-2184-3.

Article  PubMed  Google Scholar 

Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA, Movement Disorder Society-endorsed PSP Study Group. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? Mov Disord. 2017;32(7):955–71. https://doi.org/10.1002/mds.27038.

Article  PubMed  PubMed Central  Google Scholar 

Höglinger GU, Schöpe J, Stamelou M, Kassubek J, Del Ser T, Boxer AL, Wagenpfeil S, Huppertz HJ, AL-108-231 Investigators; Tauros MRI Investigators; Movement Disorder Society-Endorsed PSP Study Group. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: a new combined score for clinical trials. Mov Disord. 2017;32(6):842–52. https://doi.org/10.1002/mds.26973.

Article  PubMed  PubMed Central  Google Scholar 

Ofori E, Krismer F, Burciu RG, Pasternak O, McCracken JL, Lewis MM, Du G, McFarland NR, Okun MS, Poewe W, Mueller C, Gizewski ER, Schocke M, Kremser C, Li H, Huang X, Seppi K, Vaillancourt DE. Free water improves detection of changes in the substantia nigra in parkinsonism: a multisite study. Mov Disord. 2017;32(10):1457–64. https://doi.org/10.1002/mds.27100.

Article  PubMed  PubMed Central  Google Scholar 

Whitwell JL, Lowe VJ, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG, Spychalla AJ, Petersen RC, Jack CR Jr, Josephs KA. [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017;32(1):124–33. https://doi.org/10.1002/mds.26834.

Article  CAS  PubMed  Google Scholar 

Cho H, Choi JY, Hwang MS, Lee SH, Ryu YH, Lee MS, Lyoo CH. Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2017;32(1):134–40. https://doi.org/10.1002/mds.26844.

Article  CAS  PubMed  Google Scholar 

Whitwell JL, Tosakulwong N, Schwarz CG, Botha H, Senjem ML, Spychalla AJ, Ahlskog JE, Knopman DS, Petersen RC, Jack CR Jr, Lowe VJ, Josephs KA. MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Mov Disord. 2019;34(1):105–13. https://doi.org/10.1002/mds.27546.

Article  CAS  PubMed  Google Scholar 

Messerschmidt K, Barthel H, Brendel M, Scherlach C, Hoffmann KT, Rauchmann BS, Rullmann M, Marek K, Villemagne VL, Rumpf JJ, Saur D, Schroeter ML, Schildan A, Patt M, Beyer L, Song M, Palleis C, Katzdobler S, Fietzek UM, Respondek G, Scheifele M, Nitschmann A, Zach C, Barret O, Madonia J, Russell D, Stephens AW, Koglin N, Roeber S, Herms J, Bötzel K, Bartenstein P, Levin J, Seibyl JP, Höglinger G, Classen J, Sabri O. German imaging initiative for tauopathies (GII4T). 18F-PI-2620 tau PET improves the imaging diagnosis of progressive supranuclear palsy. J Nucl Med. 2022;63(11):1754–60. https://doi.org/10.2967/jnumed.121.262854.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li L, Liu FT, Li M, Lu JY, Sun YM, Liang X, Bao W, Chen QS, Li XY, Zhou XY, Guan Y, Wu JJ, Yen TC, Jang MK, Luo JF, Wang J, Zuo C. Progressive supranuclear palsy neuroimage initiative (PSPNI). Clinical utility of 18 F-APN-1607 tau PET imaging in patients with progressive supranuclear palsy. Mov Disord. 2021;36(10):2314–23. https://doi.org/10.1002/mds.28672.

Article  CAS  PubMed  Google Scholar 

Tagai K, Ikoma Y, Endo H, Debnath OB, Seki C, Matsuoka K, Matsumoto H, Oya M, Hirata K, Shinotoh H, Takahata K, Kurose S, Sano Y, Ono M, Shimada H, Kawamura K, Zhang MR, Takado Y, Higuchi M. An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F-APN-1607). Neuroimage. 2022;1(264): 119763. https://doi.org/10.1016/j.neuroimage.2022.119763.

Article  CAS  Google Scholar 

Mena AM, Strafella AP. Imaging pathological tau in atypical parkinsonisms: a review. Clin Park Relat Disord. 2022;16(7): 100155. https://doi.org/10.1016/j.prdoa.2022.100155.

Article  Google Scholar 

Horie K, Barthélemy NR, Spina S, VandeVrede L, He Y, Paterson RW, Wright BA, Day GS, Davis AA, Karch CM, Seeley WW, Perrin RJ, Koppisetti RK, Shaikh F, Lago AL, Heuer HW, Ghoshal N, Gabelle A, Miller BL, Boxer AL, Bateman RJ, Sato C. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat Med. 2022;28(12):2547–54. https://doi.org/10.1038/s41591-022-02075-9. Epub 2022 Nov 24. PMID: 36424467; PMCID: PMC9800273.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246(Suppl 2):II6-15. https://doi.org/10.1007/BF03161076.

Article  PubMed  Google Scholar 

•• Roemer SF, Grinberg LT, Crary JF, Seeley WW, McKee AC, Kovacs GG, Beach TG, Duyckaerts C, Ferrer IA, Gelpi E, Lee EB, Revesz T, White CL 3rd, Yoshida M, Pereira FL, Whitney K, Ghayal NB, Dickson DW. Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy. Acta Neuropathol. 2022;144(4):603–14. https://doi.org/10.1007/s00401-022-02479-4. The latest neuropathologic criteria proposed for PSP.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44(11):2015–9. https://doi.org/10.1212/wnl.44.11.2015.

Article  CAS  PubMed  Google Scholar 

Wen Y, Zhou Y, Jiao B, Shen L. Genetics of progressive supranuclear palsy: a review. J Parkinsons Dis. 2021;11(1):93–105. https://doi.org/10.3233/JPD-202302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Bougea A. Genetics of multiple system atrophy and progressive supranuclear palsy: a systemized review of the literature. Int J Mol Sci. 2023;24(6):5281. https://doi.org/10.3390/ijms24065281. An up-to-date review on the genetics of PSP.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heckman MG, Brennan RR, Labbé C, Soto AI, Koga S, DeTure MA, Murray ME, Petersen RC, Boeve BF, van Gerpen JA, Uitti RJ, Wszolek ZK, Rademakers R, Dickson DW, Ross OA. Association of MAPT subhaplotypes with risk of progressive supranuclear palsy and severity of tau pathology. JAMA Neurol. 2019;76(6):710–7. https://doi.org/10.1001/jamaneurol.2019.0250.

Article  PubMed  PubMed Central  Google Scholar 

Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699–705. https://doi.org/10.1038/ng.859.